Shots:

• Oxford Biomedica will manufacture GMP batches for Axovant to support the ongoing and future clinical development of AXO-Lenti-PD (formerly OXB-102) to treat mod. to sev. PD based on Oxford’s LentiVector platform
• Axovant is conducting a P-II SUNRISE-PD trial with AXO-Lenti-PD while the dosing of all patients in the second cohort is completed with 6mos. safety and efficacy data- expected in the Q4’20. The CSA follows WW license agreement signed b/w the companies in Jun’2018 for AXO-Lenti-PD
• Oxford expects to manufacture AXO-Lenti-PD in its commercial-scale GMP manufacturing facilities including Oxbox in the UK- and in other facilities- as required to ensure the security of supply

­ Ref: Oxford Biomedica | Image: Oxford Biomedica